Literature DB >> 34019227

Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer's disease.

Tanyaluck Thientunyakit1,2, Thonnapong Thongpraparn3, Chakmeedaj Sethanandha3, Takahiro Yamada4, Yuichi Kimura5, Weerasak Muangpaisan6, Kazunari Ishii4,7.   

Abstract

PURPOSE: To determine the association between occipital amyloid-PET uptake and neurocognitive performance in Alzheimer's disease (AD).
MATERIALS AND METHODS: Fifty-eight participants with normal aged, mild cognitive impairment (MCI) due to AD and AD subjects who underwent F-18 florbetapir brain PET/CT scans were divided into four groups (A, normal; B, MCI; C, mild AD; and D, moderate/severe AD). Semiquantitative analyses of SUVR images were performed. The differences between groups and the correlations between florbetapir uptake and Thai Mental State Examination (TMSE) scores were determined. Significant differences were defined using a P < 0.001, uncorrected, or a P < 0.05, FWE for the voxel-based analyses with Statistical Parametric Mapping (SPM).
RESULTS: There was a slightly higher florbetapir uptake in the precuneus, parietal, and occipital association cortices in Group B > A. The occipital florbetapir uptake in Groups C and D was significantly higher than in Group A, in addition to the precuneus, anterior cingulate, posterior cingulate, temporoparietal, and frontal cortices. There was a strong negative correlation between TMSE scores and florbetapir uptake in the occipital lobe.
CONCLUSIONS: Occipital amyloid uptake is associated with clinically advanced AD, and is inversely correlated with neurocognitive performance and may be useful for evaluating AD severity.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid PET; Florbetapir; Occipital

Year:  2021        PMID: 34019227     DOI: 10.1007/s11604-021-01132-6

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  36 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

2.  Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.

Authors:  Gil D Rabinovici; Constantine Gatsonis; Charles Apgar; Kiran Chaudhary; Ilana Gareen; Lucy Hanna; James Hendrix; Bruce E Hillner; Cynthia Olson; Orit H Lesman-Segev; Justin Romanoff; Barry A Siegel; Rachel A Whitmer; Maria C Carrillo
Journal:  JAMA       Date:  2019-04-02       Impact factor: 56.272

3.  Impact of Amyloid PET Imaging in the Memory Clinic: A Systematic Review and Meta-Analysis.

Authors:  Yat-Fung Shea; Warren Barker; Maria T Greig-Gusto; David A Loewenstein; Ranjan Duara; Steven T DeKosky
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

Authors:  Osama Sabri; Marwan N Sabbagh; John Seibyl; Henryk Barthel; Hiroyasu Akatsu; Yasuomi Ouchi; Kohei Senda; Shigeo Murayama; Kenji Ishii; Masaki Takao; Thomas G Beach; Christopher C Rowe; James B Leverenz; Bernardino Ghetti; James W Ironside; Ana M Catafau; Andrew W Stephens; Andre Mueller; Norman Koglin; Anja Hoffmann; Katrin Roth; Cornelia Reininger; Walter J Schulz-Schaeffer
Journal:  Alzheimers Dement       Date:  2015-03-28       Impact factor: 21.566

5.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

Authors:  Craig Curtis; Jose E Gamez; Upinder Singh; Carl H Sadowsky; Teresa Villena; Marwan N Sabbagh; Thomas G Beach; Ranjan Duara; Adam S Fleisher; Kirk A Frey; Zuzana Walker; Arvinder Hunjan; Clive Holmes; Yavir M Escovar; Carla X Vera; Marc E Agronin; Joel Ross; Andrea Bozoki; Mary Akinola; Jiong Shi; Rik Vandenberghe; Milos D Ikonomovic; Paul F Sherwin; Igor D Grachev; Gillian Farrar; Adrian P L Smith; Christopher J Buckley; Richard McLain; Stephen Salloway
Journal:  JAMA Neurol       Date:  2015-03       Impact factor: 18.302

Review 6.  Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.

Authors:  Giovanni B Frisoni; Marina Boccardi; Frederik Barkhof; Kaj Blennow; Stefano Cappa; Konstantinos Chiotis; Jean-Francois Démonet; Valentina Garibotto; Panteleimon Giannakopoulos; Anton Gietl; Oskar Hansson; Karl Herholz; Clifford R Jack; Flavio Nobili; Agneta Nordberg; Heather M Snyder; Mara Ten Kate; Andrea Varrone; Emiliano Albanese; Stefanie Becker; Patrick Bossuyt; Maria C Carrillo; Chiara Cerami; Bruno Dubois; Valentina Gallo; Ezio Giacobini; Gabriel Gold; Samia Hurst; Anders Lönneborg; Karl-Olof Lovblad; Niklas Mattsson; José-Luis Molinuevo; Andreas U Monsch; Urs Mosimann; Alessandro Padovani; Agnese Picco; Corinna Porteri; Osman Ratib; Laure Saint-Aubert; Charles Scerri; Philip Scheltens; Jonathan M Schott; Ida Sonni; Stefan Teipel; Paolo Vineis; Pieter Jelle Visser; Yutaka Yasui; Bengt Winblad
Journal:  Lancet Neurol       Date:  2017-07-11       Impact factor: 44.182

Review 7.  Clinical Use and Utility of Amyloid Imaging.

Authors:  Henryk Barthel; Osama Sabri
Journal:  J Nucl Med       Date:  2017-08-17       Impact factor: 10.057

8.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

Authors:  Christopher M Clark; Michael J Pontecorvo; Thomas G Beach; Barry J Bedell; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Eric M Reiman; Marwan N Sabbagh; Carl H Sadowsky; Julie A Schneider; Anupa Arora; Alan P Carpenter; Matthew L Flitter; Abhinay D Joshi; Michael J Krautkramer; Ming Lu; Mark A Mintun; Daniel M Skovronsky
Journal:  Lancet Neurol       Date:  2012-06-28       Impact factor: 44.182

Review 9.  Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.

Authors:  Keith A Johnson; Satoshi Minoshima; Nicolaas I Bohnen; Kevin J Donohoe; Norman L Foster; Peter Herscovitch; Jason H Karlawish; Christopher C Rowe; Maria C Carrillo; Dean M Hartley; Saima Hedrick; Virginia Pappas; William H Thies
Journal:  J Nucl Med       Date:  2013-01-28       Impact factor: 10.057

Review 10.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

View more
  1 in total

1.  Resting-State Functional Network Topology Alterations of the Occipital Lobe Associated With Attention Impairment in Isolated Rapid Eye Movement Behavior Disorder.

Authors:  Chaofan Geng; Shenghui Wang; Zhonglin Li; Pengfei Xu; Yingying Bai; Yao Zhou; Xinyu Zhang; Yongli Li; Jiewen Zhang; Hongju Zhang
Journal:  Front Aging Neurosci       Date:  2022-04-01       Impact factor: 5.702

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.